News
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...
In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.
Hosted on MSN15d
Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth company less than two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results